PA
RUN icon

PharVision Advisers’s Sunrun RUN Stock Holding History

PharVision Advisers’s Portfolio RUN Stock Details RUN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-31,102
Closed -$572K – 539
2025
Q4 		$572K Buy
31,102
+11,403
+58% +$219K 0.29% 19
2025
Q3 		$341K Buy
+19,699
New +$264K 0.19% 154
2025
Q2 		– Sell
-11,748
Closed -$68.8K – 406
2025
Q1 		$68.8K Buy
+11,748
New +$96.8K 0.1% 258

Other funds holding RUN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
GC
Greenvale Capital London, United Kingdom $912M AUM 34.2% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PI
PGGM Investments Zeist, Netherlands $5.7B AUM 17.05% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Grantham, Mayo, Van Otterloo & Co (GMO)
Grantham, Mayo, Van Otterloo & Co (GMO) Boston, Massachusetts $39.1B AUM 28.69% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

PharVision Advisers's RUN Position: Q1 2026 in Review

PharVision Advisers sold out of Sunrun (RUN) in Q1 2026, closing a stake of 31,102 shares — an estimated $572K sold.

PharVision Advisers first reported a position in RUN in Q1 2025 and held it in 3 quarters. The position peaked at $572K in Q4 2025. 397 funds tracked by Wall St. Rank hold RUN as of Q1 2026.

  • PharVision Advisers reported no remaining Sunrun position as of Q1 2026 after selling out during the quarter.
  • PharVision Advisers sold 31,102 Sunrun shares in Q1 2026, an estimated $572K.
  • PharVision Advisers first reported a position in Sunrun in Q1 2025 and held it in 3 quarters.
  • PharVision Advisers's Sunrun position peaked at $572K in Q4 2025.
  • 397 funds tracked by Wall St. Rank held Sunrun as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.